Table 2 Descriptive statistics for %∆CDAI, ACR-N, and ∆HAQ-DI at month 12
| Â | CDAI | ACR-N | HAQ-DI | |||||
|---|---|---|---|---|---|---|---|---|
Na | Baseline, mean (SE) | %∆ at month 12, mean (SE) | Na | At month 12, mean (SE) | Na | Baseline, mean (SE) | ∆ at month 12, mean (SE) | |
Tofacitinib monotherapy | 319 | 38.7 (0.7) |  − 65.3 (1.8) | 320 | 32.2 (6.0) | 320 | 1.59 (0.04) |  − 0.63 (0.04) |
Tofacitinib + MTX | 309 | 40.5 (0.7) |  − 74.0 (1.2) | 310 | 49.1 (2.1) | 311 | 1.57 (0.04) |  − 0.67 (0.04) |
ADA + MTX | 312 | 38.3 (0.8) |  − 72.2 (1.4) | 314 | 45.1 (2.8) | 313 | 1.55 (0.04) |  − 0.67 (0.03) |